Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis

Table 2 Subgroup analysis of the relationships between oligodendrocyte transcription factor 2 expression and overall survival

Comparison variables	Number of studies	Number of people	HR and 95%CI	P value	Heterogeneity by I2 statistics
Total	6	1205	0.81 (0.51-1.27)	0.000	84.5
Country
Europe	3	736	1.34 (0.79-2.27)	0.008	79.3
Asian	3	469	0.43 (0.22-0.84)	0.027	72.3
number
> 150	3	900	1.10 (0.65-1.86)	0.001	86.7
≤ 50	3	305	0.46 (0.17-1.29)	0.002	84.0
Median age
> 50	4	980	0.96 (0.50-1.84)	0.000	85.8
≤ 50	1	73	0.11 (0.03-0.40)	-	-
No referred	1	152	0.98 (0.84-1.15)	-	-
WHO grade
II-III	2	404	1.47 (0.62-3.47)	0.002	89.6
IV	4	801	0.72 (0.36-1.45)	0.000	87.0
Method
Reported	2	623	1.47 (0.62-3.47)	0.002	89.6
K-M curve	4	582	0.56 (0.31-1.01)	0.006	76.0
Cut-off
> 10	1	73	0.11 (0.03-0.40)	0.000	85.8
≤ 10	4	980	0.96 (0.50-1.84)	-	-
Follow up time
> 50	2	396	0.60 (0.45-0.81)	0.366	0.0
≤ 50	3	338	0.67 (0.31-1.46)	0.003	82.6

HR: Hazard ratio; K-M: Kaplan-Meier; WHO: World Health Organization.